Customized Radiation of Uterus in Cervical Cancer May Not Compromise Outcomes

  • 📰 Medscape
  • ⏱ Reading Time:
  • 79 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 35%
  • Publisher: 55%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

Researchers found that patients with locally advanced cervical cancer who received less than whole uterus irradiation had low local recurrence rates and fewer side effects.

receiving chemoradiation, irradiating less than whole uterus led to a low local recurrence rate and less radiation to the bowel but significantly higher locoregional recurrence.At a single institution, researchers developed a more individualized clinical target volume based on the tumor volume that involved the cervix and accounted for organ movement when the bladder was full or empty to decrease radiation to the surrounding bowel.

The researchers identified 109 patients with locally advanced cervical cancer , who received concurrent chemoradiation therapy following this method between 2011 and 2022. Patients underwent external beam radiation therapy using IMRT at a dose of 48.6 Gy delivered in 27 fractions, followed by a boost to 54.0-61.9 Gy targeting the involved lymph nodes. Subsequently, patients received high-dose-rate brachytherapy boost to 27.5-30.0 Gy, employing 5.5-7.0 Gy per fraction. Overall, 53 patients had ≥ 75% of the uterus included in the planning target volume, and 56 had < 75% included.

In patients with ≥ 75% of the uterus included in the final planning target volume, the 2-year cumulative incidence of locoregional recurrence was significantly lower than in patients with < 75% of the uterus included . However, the ≥ 75% group also received a significantly higher dose of radiation to the bowel than those with less uterus included experienced acute grade ≥ 3 gastrointestinal toxicities, and 2 patients experienced late grade ≥ 3 genitourinary toxicities.

"Less than whole uterus irradiation could be considered for carefully selected cervix cancer patients to decrease bowel dose and possible treatment-related toxicity," the team added.The retrospective study design introduced inherent biases. The patient cohort spanned over a decade, making it heterogeneous. A small number of patients lacked an initial staging MRI scan. Retrospective toxicity scoring may have caused underestimation of the actual risk for prospective morbidity.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 386. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Combining Targeted Drugs and Radiation in Breast Cancer: What's Safe?There are surprisingly little data on how to safely combine new targeted treatments for breast cancer alongside radiotherapy. Experts weigh in on what we know.
Source: Medscape - 🏆 386. / 55 Read more »